Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, open-label, three-treatment, crossover study of Pharmacokinetics and Safety of the PROteolysis Targeting Chimera Androgen Receptor Degrader Bavdegalutamide in Healthy Volunteers

Next Previous
Search
Trial Profile

Phase 1, open-label, three-treatment, crossover study of Pharmacokinetics and Safety of the PROteolysis Targeting Chimera Androgen Receptor Degrader Bavdegalutamide in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bavdegalutamide (Primary) ; Esomeprazole
  • Indications Prostate cancer
  • Focus Pharmacokinetics

Most Recent Events

  • 02 Nov 2023 New trial record
  • 12 Sep 2023 Results (n=16) assessing The Effect of Food & the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of the PROteolysis Targeting Chimera Androgen Receptor Degrader Bavdegalutamide in Healthy Volunteers presented at the 2023 American College of Clinical Pharmacology Annual Meeting

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top